4 Jan 2010 13:43
Epistem Holdings Plc ("Epistem" or the "Company")
Directors' Shareholdings
Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 258 ordinary shares of 1.5p each. These shares were acquired in tranches at the end of October, November and December at prices of 385p, 438p and 470p respectively.
The current beneficial interests of the executive Directors are set out below:
| Matthew Walls | 6,652 | (0.08%) |
| Dr Catherine Booth | 981,007 | (12.36%) |
| Dr Ged Brady | 1,007 | (0.01%) |
| Dr Jeffrey Moore | 15,507 | (0.20%) |
| John Rylands | 190,905 | (2.41%) |
For further details please contact:
| Epistem Plc | |
| Matthew Walls, CEO | +44 161 606 7258 |
| Piper Jaffray Ltd. | |
| Neil Mackison / Rupert Winckler | +44 20 3142 8700 |
Genedrive (GDR)